Skip to content
ClinCalc Pro
Menu
Mycobacterial antigen for delayed-type hypersensitivity testing

Tuberculin purified protein derivative

Tuberculin purified protein derivative is a diagnostic preparation of mycobacterial antigens used intradermally in the Mantoux test to assess cell-mediated immunity to tuberculosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Intradermal antigen elicits a delayed-type hypersensitivity response in sensitised individuals, producing a measurable area of skin induration after a defined interval.

Prescribing in practice

  • It must be given strictly intradermally and the result read as induration at the specified time, as incorrect technique or timing invalidates interpretation.
  • Results require clinical interpretation, since prior BCG vaccination, some infections, and immunosuppression can cause false-positive or false-negative reactions.
  • A positive test indicates immune sensitisation and does not by itself distinguish latent infection from active tuberculosis disease.

Monitoring

Ensure the reaction is read by trained staff at the correct interval, measuring induration rather than erythema, and interpret alongside the clinical picture.

Counselling the patient

  • You must return at the specified time to have the test site measured.
  • A raised firm area, not redness alone, is what is measured.
  • The result will be interpreted together with your history and other tests.

Evidence & guidelines

The Mantoux tuberculin test is the standard intradermal method for assessing tuberculosis infection in UK NICE and Health Security Agency guidance.

Reference: UKHSA Green Book Ch.32; NICE NG33; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.